Best of ASH & SABCS 2024, Portland

Portland, OR US
January 12, 2024 to January 13, 2024

The Best of ASH & SABCS 2024, Portland, is a CME-accredited, in-person hematology oncology conference featuring leading hematology and breast cancer experts. Expert faculty will place key abstract findings from the 65th ASH Annual Meeting (ASH2023) and the San Antonio Breast Cancer Symposium (SABCS2023) into clinical context and discuss how the results may change the current standards of care for patients with benign and malignant hematologic disorders and breast cancer. This conference is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care.

This conference allows attendees an opportunity to discuss current research and advances in the field of hematologic disorders and breast cancer with colleagues and key opinion leaders. The goals of this conference are to review and critically assess the results of practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients. 

Target Audience

  • Hematologists, Oncologists
  • Surgeons
  • Radiation Oncologists
  • Physician Assistants/Nurse Practitioners
  • Pharmacists
  • Nurses

Organizing Committee

Conference Director: 

Binay Shah, MD, MHA - Binaytara Foundation

Conference Co-Chairs:

Curtis Lachowiez, MD - Oregon Health & Science University

Sasha Stanton, MD, PhD - Providence Cancer Institute

Venue Link: 

If you are attending this meeting and need to book your hotel room, please use the link below to take advantage of the discounted group rate of $149/night. The deadline to book under the group rate is December 29, 2023.

https://www.hilton.com/en/attend-my-event/ashsabcsportlandjan2024/

Learning Objectives

  1. Review data presented at the ASH2023 and SABCS2023 & discuss their applications in clinical settings.    
  2. Choose new therapeutic options for treating benign and malignant hematologic disorders & breast cancer, understanding appropriate indications and contraindications to these therapeutic approaches.
  3. Discuss the study design and primary endpoints of recently reported and ongoing trials that have influenced the changes in the standards of care in hematology and breast cancer.
  4. Integrate evolving diagnostic, prognostic, and therapeutic approaches to managing hematologic disorders and breast cancer patients.
  5. Individualize management of patients based on emerging data from clinical trials and evolving expert guidelines.

GLOBAL ONCOLOGY PROJECT

To learn more about our ongoing project building a 200-bed cancer hospital in Nepal:

Course summary
Available credit: 
  • 8.25 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.25 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.25 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.25 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.25 Contact Hours.
Course opens: 
09/21/2023
Course expires: 
03/31/2024
Event starts: 
01/12/2024 - 5:00pm PST
Event ends: 
01/13/2024 - 4:35pm PST
Cost:
$150.00

DAY 1 - January 12, 2024

All times are listed in Pacific Time (PT)

04:00 – 04:45 PM: Registration and networking


04:45 – 05:00 PM: Opening remarks


05:00 – 06:30 PM: Session I – Case-based discussion

Moderator: 

Case 1 - Bleeding disorder - Joseph Shatzel, MD

Case 2 - Clotting disorder - Sven Olson, MD

Case 3 - ITP/TTP

Case 4 - Anemia - Sunny Kim, MD

Case 5 - Bone marrow failure - Yazan Migdady MD, MSc


06:30 – 07:15 PM: Networking and reception


DAY 2 - January 13, 2024

07:00 AM – 07:55 AM: Breakfast and exhibits


08:00 – 09:30 AM: Session II 

Moderator: Elie Traer, MD, PhD

08:00 - 08:25 AM: MDS/Acute Leukemia - Anna B. Halpern, MD

08:25 - 08:50 AM: Myeloproliferative neoplasms and CML - Arpita Gandhi, MD, MS

08:50 - 09:15 AM: Cellular therapy in hematologic malignancies – recent updates - Rachel J. Cook, MD, MS

09:15 - 09:30 AM: Q & A


09:30 – 10:00 AM:  Break and exhibits


10:00 – 11:45 AM: Session III

Moderator: Rebecca Silbermann MD, MMS

10:00 - 10:25 AM: Lymphoma - Craig Okada, MD

10:25 - 10:50 AM: Chronic lymphocytic leukemia - Parameswaran Venugopal, MD

10:50 - 11:15 AM: Multiple myeloma - Rahul Banerjee, MD, FACP

11:15 - 11:45 AM: Q & A


11:45 AM – 12:45 PM: Lunch and exhibits


12:45 – 02:25 PM: Session IV

Moderator: Sasha E. Stanton, MD, PhD

12:45 - 01:10 PM: Pre-malignancy/high risk breast cancer - Alison K. Conlin, MD

01:10 - 01:35 PM: Hormone receptor positive breast cancer - Evie A. Hobbs, MD

01:35 - 02:00 PM: HER2 positive breast cancer - David B. Page, MD

02:00 - 02:25 PM: Triple negative and HER2 low breast cancer - Nora Bucher, MD


02:25 – 02:40 PM: Break and exhibits


02:40 – 04:30 PM: Session V

Moderator: Sasha E. Stanton, MD, PhD

02:40 - 03:05 PM: Radiotherapy – best breast practice - Kiri Cook, MD

03:05 - 03:30 PM: Updates in surgical approach – best breast practice - Kristen P. Massimino, MD

03:30 - 03:45 PM: Q & A

03:45 - 04:30 PM: Case-based discussion

Case 1 - DCIS - Sasha E. Stanton, MD, PhD

Case 2 - Inflammatory breast cancer - Janet C. Ruzich, DO

Case 3 - Early stage breast cancer - Kathleen Dunham, MD


04:30 – 04:35 PM: Adjourn

Embassy Suites by Hilton Portland Downtown
319 SW Pine Street
Portland, OR 97204
United States

If you are attending this meeting and need to book your hotel room, please use the link below to take advantage of the discounted group rate of $149/night. The deadline to book under the group rate is December 29, 2023.

https://www.hilton.com/en/attend-my-event/ashsabcsportlandjan2024/

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Course Director(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.
Conference Chair(s)

Curtis Lachowiez, M.D.

has a financial relationship (Independent contractor) with COTA Healthcare;.
Speaker/Topic Presenter(s)

Rahul Banerjee, MD, FACP

has a financial relationship (Grant Or Contract) with i3 Health;.
has a financial relationship (Independent contractor) with Clearview Healthcare Partners;.
has a financial relationship (Independent contractor) with Guidepoint Global;.
has a financial relationship (Grant Or Contract) with Pack Health;.
has a financial relationship (Grant Or Contract) with Clinical Care Options;.
has a financial relationship (Independent contractor) with Sanofi Pasteur;.
has a financial relationship (Independent contractor) with Janssen Oncology;.
has a financial relationship (Grant Or Contract) with Curio Science;.
has a financial relationship (Independent contractor) with SparkCures;.
has a financial relationship (Independent contractor) with Genentech/Roche;.

Alison Conlin, Md, Mph

has no relevant financial relationships to disclose at this time.

Kiri Cook, MD

has no relevant financial relationships to disclose at this time.

Anna Halpern, MD

has a financial relationship (Other) with Imago Biosciences;.
has a financial relationship (Professional Services) with Notable Labs;.
has a financial relationship (Other) with Jazz pharmaceuticals;.
has a financial relationship (Other) with Incytes Pharmaceuticals;.
has a financial relationship (Other) with Bayer;.
has a financial relationship (Other) with Karyopharm Therapeutics;.
has a financial relationship (Other) with Gilead Sciences;.

Kristen Massimino, MD FACS, FSSO

has no relevant financial relationships to disclose at this time.

Craig Okada

has no relevant financial relationships to disclose at this time.

Parameswaran Venugopal, MD

has a financial relationship (Professional Services) with BeiGene;.
Case Presenter(s)

Kathleen Dunham

has no relevant financial relationships to disclose at this time.

Available Credit

  • 8.25 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.25 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.25 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.25 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.25 Contact Hours.

If you are interested in exhibiting at this meeting, please contact Tara Shah at (425) 361-0377 or email sponsorships@binayfoundation.org.

Exhibit Materials Shipping Instructions:

Please send packages to:

Embassy Suites by Hilton Portland Downtown

HOLD FOR GUEST John Doe / Arrival XX/XX/2023

319 SW Pine St, Portland, OR 97204.

Price

Cost:
$150.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.